Redhill Biopharma Ltd.

RDHL Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
RDHL Income Statement
RDHL Balance Sheet
RDHL Cash Flow
Congress Trading

Recent trades of RDHL by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
RDHL Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
RDHL Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
RDHL Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RDHL's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Biomarkers of coronavirus pneumonia Oct. 15, 2024
  • Patent Title: All-in-one fixed-dose combination for treating Mar. 19, 2024
  • Patent Title: Serine protease inhibitor for treating coronavirus infection Mar. 05, 2024
  • Patent Title: Method for eradicating Jan. 23, 2024
  • Patent Title: Inhibitor of sphingosine kinase 2 for treating ebola Oct. 17, 2023
  • Patent Title: Combination compositions for treatment of cancer Apr. 25, 2023
  • Patent Title: Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections Feb. 28, 2023
  • Patent Title: Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia Oct. 18, 2022
  • Patent Title: Sphingosine kinase 2 inhibitor for treating coronavirus infection Jun. 21, 2022
  • Patent Title: Rifabutin-based compositions and methods for treating Oct. 05, 2021
  • Patent Title: Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine Aug. 17, 2021
  • Patent Title: Compositions for treating ebola virus infection Aug. 17, 2021
  • Patent Title: Formulations and methods of manufacturing formulations for use in colonic evacuation Jul. 13, 2021
  • Patent Title: Sphingosine kinase 2 inhibitor for treating coronavirus infection Jul. 06, 2021
  • Patent Title: Serine protease inhibitor for treating coronavirus infection Jun. 29, 2021
  • Patent Title: Method for treating cancer with combination therapy Mar. 16, 2021
  • Patent Title: Methods for treating helicobacter pylori infection Jan. 26, 2021
  • Patent Title: Method for treating crohn's disease using triple antimicrobial all-in-one formulation Sep. 08, 2020
  • Patent Title: Compositions, methods and kits for treating diarrhea-predominant irritable bowel syndrome Jun. 02, 2020
  • Patent Title: Blister package May. 12, 2020
  • Patent Title: Therapy for inhibition of single-stranded rna virus replication Jan. 28, 2020
  • Patent Title: Formulations and methods of manufacturing formulations for use in colonic evacuation Dec. 03, 2019
  • Patent Title: Combination therapies for treating cancer Nov. 05, 2019
  • Patent Title: Methods of treating a bacterial infection using a fixed-dose pharmaceutical composition comprising three antibiotics Oct. 08, 2019
  • Patent Title: Pharmaceutical compositions for the treatment of Mar. 26, 2019
  • Patent Title: Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine Dec. 04, 2018
  • Patent Title: Therapy for inhibition of single-stranded rna virus replication May. 22, 2018
  • Patent Title: Composition and method for treating an autoimmune disease Feb. 27, 2018
  • Patent Title: Combination therapies for treating cancer Dec. 19, 2017
  • Patent Title: Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms Jun. 13, 2017
  • Patent Title: Antiemetic extended release solid dosage forms May. 02, 2017
  • Patent Title: Pharmaceutical compositions for the treatment of Mar. 28, 2017
  • Patent Title: Pharmaceutical compositions for the treatment of Nov. 22, 2016
  • Patent Title: Compositions comprising rifabutin, clarithromycin, and clofazimine and uses thereof Apr. 19, 2016
  • Patent Title: Methods and compositions comprising rifabutin, clarithromycin, and clofazimine Dec. 01, 2015
  • Patent Title: Methods and compositions for treating inflammatory bowel disease Jul. 07, 2015
  • Patent Title: Pharmaceutical compositions for the treatment of Jun. 09, 2015
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of RDHL in WallStreetBets Daily Discussion

RDHL News

Recent insights relating to RDHL

CNBC Recommendations

Recent picks made for RDHL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RDHL

RDHL Top Shareholders
Shareholder
Shares Held
RDHL Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

RDHL Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view RDHL Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top